$ABC PENNY STOCK ALERTS ~ WHEN THE PRICE IS RIGHT $

[FinlayS00]

$LUDG - Ludwig Enterprises is pleased to announce that the Company has started discussions with Emerson Urology Associates, Concord, MA regarding the initiation of a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy. A confidentiality agreement has been signed with Dr. John Libertino, MD, Director of Emerson Urology Associates.

The objective of the joint research program between Ludwig Enterprises and Emerson Urology Associates is to use Ludwig's proprietary genetic inflammatory markers to study patients with early-stage superficial bladder cancer and assess therapeutic response to BCG immunotherapy.

Ludwig's proprietary genetic inflammatory biomarker panel is in the process of being submitted to the U.S. Patent office.

https://finance.yahoo.com/news/ludwig-enterprises-emerson-urology-associates-113000319.html